|GRANTWAY
EN

New Approaches for Incorporating Genetic Diversity into Toxicity Testing (R43/R44 Clinical Trial Not Allowed)

National Institutes of Health

Share
Favorite
Feedback
Summary
-
08 November 2022
-
-
-
For profit
United States of America
Energy, Climate and Environment Health, Justice and Social Welfare
Research, Development and Innovation Natural Sciences
Research, Development and Innovation Social Sciences
Overview

This Funding Opportunity Announcement (FOA) supports Phase I (R43), Phase II (R44), Direct to Phase II (R44), and Fast Track (R44) Small Business Innovative Research (SBIR) grant applications from small businesses concerns (SBCs) to develop resources and approaches, including panels of cells or model organisms, that reflect the variability in human populations in chemical toxicity testing . Current toxicology testing is often limited to studies conducted in a small number of laboratory rodent strains, which can fail to identify clinically relevant toxicity if the conventional rodent strain is particularly resistant to the toxic effects of the test compound. Cost-effective screening systems with appropriate throughput are needed to better capture this variability in responses to chemical exposure in the population based on individual genetic susceptibility.

Eligibility

Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed

Learn more or apply
All information about this funding has been collected from and belongs to the funding organization
20 April 2023